EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022

Helio S Sader iD, Jennifer I Smart, Rodrigo E Mendes, Mariana Castanheira

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01402-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Helio S Sader und 3 weiteren Autor:innen. Beteiligte Einrichtung: JMI Laboratories, Element Materials Technology, North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Cephalosporins, Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ceftobiprole was recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with Staphylococcus aureus bacteremia, including right-side endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in adults and pediatrics. Ceftobiprole is an advanced-generation cephalosporin approved in many countries for the treatment of adults with community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia. We evaluated the activities of ceftobiprole and comparators against methicillin-resistant S. aureus (MRSA) and multidrug-resistant (MDR) S. aureus clinical isolates. A total of 19,764 S . aureus isolates were collected from patients with various infection types at 37 US medical centers from 2016 to 2022. Susceptibility testing was performed by broth microdilution according to Clinical and Laboratory Standard Institutes (CLSI) standards. Isolates were categorized as MDR if they were nonsusceptible by CLSI criteria to ≥3 antimicrobials. Ceftobiprole was highly active against MRSA ( n = 8,184; MIC 50/90 , 1/2 mg/L; 99.3% susceptible [S]) and MDR ( n = 2,789; MIC 50/90 , 1/2 mg/L; 98.1%S) isolates and retained activity against 87.3% of ceftaroline-nonsusceptible isolates ( n = 433; MIC 50/90 , 2/4 mg/L). Ceftobiprole demonstrated greater susceptibility rates than ceftaroline against all resistant subsets. Ceftobiprole was highly active against isolates nonsusceptible to clindamycin (98.0%S), daptomycin (100.0%S), doxycycline (98.2%S), erythromycin (99.5%S), gentamicin (98.1%S), levofloxacin (99.1%S), tetracycline (99.1%S), tigecycline (100.0%S), and trimethoprim-sulfamethoxazole (99.4%S) and isolates with decreased susceptibility to vancomycin (98.3%S).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CephalosporinsAnti-Bacterial AgentsMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsHumansUnited StatesDrug Resistance, Multiple, BacterialStaphylococcal InfectionsCommunity-Acquired InfectionsStaphylococcus aureus

Stichwörter der Autor:innen

MRSAbacteremiaceftarolineceftobiprolecephalosporinpneumoniaskin and skin structure infection

Substanzen

CephalosporinsAnti-Bacterial Agentsceftobiprole

Autor:innen und Institutionen

  • JMI Laboratories, Element Materials Technology, North Liberty, Iowa, USA.
  • Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.

ORCID-Profile: Helio S Sader

Zitieren

APA

Sader, H. S., Smart, J. I., Mendes, R. E., & Castanheira, M. (2025). Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01402-24

Vancouver

Sader HS, Smart JI, Mendes RE, Castanheira M. Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01402-24

BibTeX
@article{Sader2025,
  author = {Sader, Helio S and Smart, Jennifer I and Mendes, Rodrigo E and Castanheira, Mariana},
  title = {Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01402-24}
}
Kostenlos starten →